MetaCap

NervGen Pharma (NGEN) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vanda Pharmaceuticals (VNDA) has outperformed NervGen Pharma (NGEN) over the past year, losing 28.2% versus a loss of 35.0%. Over five years, NGEN leads with a -9.6% price change compared with -79.2% for VNDA. Vanda Pharmaceuticals is the larger company by market cap ($208.3 million vs $198.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NGEN-35.04%VNDA-28.23%
+118%+28%-62%
Nov 21, 20251 yearNov 20, 2026
NGEN-16.85%VNDA-79.69%
+177%+43%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NGEN versus VNDA key metrics
MetricNGENVNDA
Share price$1.85$3.45
Market cap$198.55M$208.32M
1-day change-3.91%-6.13%
YTD return-67.05%-60.94%
1-year return-35.04%-28.23%
5-year return-9.56%-79.18%
Forward P/E—17.22
EPS (TTM)$-0.24$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$216.10M
Revenue growth (YoY)—+8.72%
Net income (latest FY)—$-220.47M
Gross margin—93.96%
Operating margin—-69.95%
Net margin—-102.02%
52-week high$6.30$9.94
52-week low$1.28$3.42
Distance from 52-week high-70.71%-65.34%
Analyst consensusstrong_buynone
Avg. price target upside+442.01%+233.82%
Average volume621.66K1.06M
Shares outstanding107.62M60.47M
Employees9533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NervGen Pharma

NGEN stock →

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

NGEN vs VNDA FAQ

Which is bigger, NervGen Pharma or Vanda Pharmaceuticals?

Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $208.32M compared with $198.55M for NervGen Pharma (NGEN).

Which stock has performed better over the past year, NGEN or VNDA?

VNDA returned -28.23% over the past 12 months, compared with -35.04% for NGEN (price return, excluding dividends). Past performance does not predict future results.

Are NervGen Pharma and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons